EI
REGN icon

Ethic Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Ethic Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6M Sell
15,017
-926
-6% -$709K 0.18% 113
2025
Q4 		$12.3M Sell
15,943
-550
-3% -$374K 0.19% 103
2025
Q3 		$9.27M Sell
16,493
-354
-2% -$200K 0.15% 138
2025
Q2 		$8.78M Buy
16,847
+9,766
+138% +$5.45M 0.16% 133
2025
Q1 		$4.37M Sell
7,081
-3,587
-34% -$2.47M 0.09% 235
2024
Q4 		$7.6M Buy
10,668
+4,509
+73% +$3.78M 0.15% 138
2024
Q3 		$5.93M Sell
6,159
-284
-4% -$316K 0.15% 164
2024
Q2 		$6.77M Buy
6,443
+284
+5% +$275K 0.16% 138
2024
Q1 		$5.93M Buy
6,159
+602
+11% +$572K 0.15% 164
2023
Q4 		$4.88M Sell
5,557
-261
-4% -$215K 0.14% 172
2023
Q3 		$4.79M Buy
5,818
+177
+3% +$139K 0.17% 143
2023
Q2 		$4.05M Buy
5,641
+60
+1% +$46.3K 0.15% 168
2023
Q1 		$4.59M Buy
5,581
+2,271
+69% +$1.71M 0.19% 128
2022
Q4 		$2.39M Buy
3,310
+876
+36% +$646K 0.13% 210
2022
Q3 		$1.68M Sell
2,434
-37
-1% -$23.3K 0.11% 227
2022
Q2 		$1.46M Buy
2,471
+542
+28% +$352K 0.1% 249
2022
Q1 		$1.35M Buy
1,929
+404
+26% +$256K 0.09% 266
2021
Q4 		$963K Buy
1,525
+132
+9% +$81.2K 0.07% 287
2021
Q3 		$843K Buy
1,393
+355
+34% +$220K 0.09% 258
2021
Q2 		$580K Buy
1,038
+290
+39% +$147K 0.07% 306
2021
Q1 		$354K Sell
748
-119
-14% -$57.9K 0.06% 344
2020
Q4 		$419K Buy
867
+45
+5% +$24.3K 0.11% 243
2020
Q3 		$460K Buy
822
+221
+37% +$134K 0.18% 142
2020
Q2 		$375K Buy
601
+130
+28% +$73.8K 0.21% 134
2020
Q1 		$230K Buy
+471
New +$194K 0.19% 165

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ethic Inc's REGN Position: Q1 2026 in Review

Ethic Inc reduced its Regeneron Pharmaceuticals (REGN) stake by 5.8% in Q1 2026, selling an estimated $709K and leaving 15,017 shares worth $11.6M. The position accounts for 0.18% of the portfolio, ranked #113.

Ethic Inc first reported a position in REGN in Q1 2020 and has held it in 25 quarters since. The position peaked at $12.3M in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Ethic Inc held 15,017 shares of Regeneron Pharmaceuticals worth $11.6M as of Q1 2026.
  • Ethic Inc sold 926 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $709K.
  • Regeneron Pharmaceuticals made up 0.18% of Ethic Inc's portfolio in Q1 2026, its #113 holding.
  • Ethic Inc first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • Ethic Inc's Regeneron Pharmaceuticals position peaked at $12.3M in Q4 2025.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Ethic Inc's 13F filing for Q1 2026, filed 27 Apr 2026.